It is noteworthy that a small proportion of participants had a tumor with HER-2-positive subtype and negative hormone receptor in our study, and none presented a complete pathological response, despite the fact that these tumors exhibit the highest response rate described in the literature [3]. This evidence concerns the gene ERBB2 and neoplasm.